Trend
DailyUptrend (starting)
4 hourExpanding
1 hourSymmetric Triangle
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $1.35
Key levels
Resistance$3.46
Resistance$3.20
Support$2.90
Support$2.43
Latest news & SEC filings
EarningsX4 Pharmaceuticals Posts Q3 2026 Financials
ProductMavorixafor receives FDA Fast Track status for chronic neutropenia
EarningsX4 Pharmaceuticals posts smaller quarterly loss than expected, revenue tops forecast
All XFOR news →X4 Pharmaceuticals is a biopharmaceutical company focused on rare blood disorders. It sells XOLREMDI (mavorixafor), a once-daily oral medicine cleared in the United States for WHIM syndrome in patients aged 12 and up. The company is also running a late-stage study of mavorixafor in chronic neutropenia. It operates mainly in the United States and works with partners covering Europe, the Middle East, and China.
Based on the company's 10-K filed Mar 17, 2026.
Nasdaq · Healthcare
SEPT Low Target
$9.35
SEPT Mid Target
$11.00
SEPT High Target
$12.65
Analyst Consensus
$11.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for XFOR.
Start Free Trial →Valuation Verdict
UNDERVALUED
Methods Used
P/B, PEG, Analyst Consensus
Fair Value
$8.12
12
Moat Score
NONE
3/9
Piotroski Score
-2.2
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 2 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
DISTRIBUTING
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Craig Adam R | director officer | Buy | 4,600 | $12K | Oct 16, 2026 |
| KIRSKE DAVID | officer | Sale | 11,767 | $34K | Oct 1, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
150.0%
3yr Revenue CAGR
N/A%
EPS Growth YoY
66.55%
FCF Growth YoY
34.8%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for XFOR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:22 | $3.23 | 1,834 | $$6K | BUY |
| 20:59:54 | $3.22 | 1,000 | $$3K | BUY |
| 20:58:04 | $3.24 | 1,000 | $$3K | BUY |
| 20:58:03 | $3.24 | 2,000 | $$6K | SELL |
| 20:52:26 | $3.21 | 2,000 | $$6K | SELL |
5 dark pool trades shown · $$25K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for X4 Pharmaceuticals, Inc (XFOR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (2 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →X4 Pharmaceuticals, Inc (XFOR) is at $3.14, down 2.79% (-$0.09) at the Nov 12, 2026 close.
Latest XFOR news — Nov 5, 2026: X4 Pharmaceuticals Posts Q3 2026 Financials · Nov 4, 2026: Mavorixafor receives FDA Fast Track status for chronic neutropenia
The average analyst price target for XFOR is $11.00, ranging from $11 to $11, based on 1 analysts. Latest: Wells Fargo initiates on Jul 10, 2026.
Analyst ratings for XFOR: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
XFOR last reported on Aug 6, 2026: EPS -$0.13 vs -$0.18 expected — a beat of 26.1%.
XFOR does not currently pay a dividend.
X4 Pharmaceuticals, Inc reported $75M of debt and $195M of cash (Jun 30, 2026).
Support: $2.90, $2.43. Resistance: $3.20, $3.46, $3.84.
Insider activity: NEUTRAL, 0 buys and 2 sells in the last 90 days.
Nov 5, 2026: X4 Pharmaceuticals Posts Q3 2026 Financials · Nov 4, 2026: Mavorixafor receives FDA Fast Track status for chronic neutropenia · Nov 4, 2026: X4 Pharmaceuticals posts smaller quarterly loss than expected, revenue tops forecast